LOGIN
REQUEST WALKTHROUGH
search
times
New call-to-action

Tags

See all

Articles

PNV

PolyNovo Limited Rallies 7% On The Back Of Big Announcement

Tumul Sinha

Tumul is an experienced Equity Analyst with ASR Wealth Advisers. She holds a Master’s Degree in Finance from the University of Sydney. Her key industry verticals include Real Estate, Health Care and Technology.

PolyNovo Limited (ASX: PNV) has opened up over 7% this trading session, getting as high as $2.73 per share, making it the best performer in the ASX 200 today. The rally comes on the back of an announcement the company made this morning, outlining their success in breaking into the European market.

OGA5I60

PolyNovo Limited (ASX: PNV) has opened this trading session up over 7% after an ASX announcement outlining their success in cracking into the European market. The company has sold its flagship product to a company in Germany, Austria and Switzerland. (Credit: PolyNovo.com)


PolyNovo is an Australian developer of unique, patented, biodegradable polymers for use in medical devices. The company provides regenerative products for burns, surgical wounds, orthopedics and reconstructive surgery amongst other health issues.


The company’s ASX announcement included several positives for the company, including their first product order of their flagship biodegradable temporizing matrix (BTM) product from medical device company PolyMedics Innovation (PMI) for their branches in Germany, Austria and Switzerland. Furthermore, PolyNovo’s BTM product is being used in surgery for the first time on Sunday in Germany. PNV also announced that there are a number of surgeons that plan to use BTM in upcoming surgeries in the coming week and fortnight.


Today’s announcement is just more great news for the company that is looking to break into an opportunistic and lucrative European market. The stock has rallied 30 fold in the past 5 years and 335% in the past year alone. The company is expected to breakeven in FY20 and is currently trading on a forward FY21 consensus multiple of 175x earnings and a FY22 consensus multiple of 94x, meaning that the market expects PNV’s earnings to grow significantly through the next few years.

 


 

Disclaimer:
This article has been prepared by the Australian Stock Report Pty Ltd (AFSL: 301 682. ABN: 94 106 863 978)
(“ASR”). ASR is part of Amalgamated Australian Investment Group Limited (AAIG) (ABN: 81 140 208 288 Level 13, 130 Pitt Street, Sydney NSW 2000).
This article is provided for informational purpose only and does not purport to contain all matters relevant to any particular investment or financial instrument. Any market commentary in this communication is not intended to constitute “research” as defined by applicable regulations. Whilst information published on or accessed via this website is believed to be reliable, as far as permitted by law, we make no representations as to its ongoing availability, accuracy or completeness. Any quotes or prices used herein are current at the time of preparation. This document and its contents are proprietary information and products of our firm and may not be reproduced or otherwise disseminated in whole or in part without our written consent unless required to by judicial or administrative proceeding. The ultimate decision to proceed with any transaction rests solely with you. We are not acting as your advisor in relation to any information contained herein. Any projections are estimates only and may not be realised in the future.
ASR has no position in any of the stocks mentioned.
New call-to-action
New call-to-action

Company Articles

Looking for more Stock Recommendations?

Fill in your details to receive our special report: Top 3 Income Stock Recommendations for 2020.